Literature DB >> 18545231

Invasive mycoses in children receiving hemopoietic SCT.

E Castagnola1, M Faraci, C Moroni, R Bandettini, C Granata, S Caruso, F Bagnasco, I Caviglia, M Malgorzata, E Furfaro, A R Natalizia, V de Fazio, G Morreale, E Lanino, R Haupt, G Dini, C Viscoli.   

Abstract

Invasive mycoses represent a rare but severe complication following hemopoietic SCT (HSCT) in children. Their incidence is related to the type of donor, being higher after allogeneic transplant, especially from alternative donors. Moreover, the incidence of invasive mycoses varies in the different post transplant phases. Neutropenia, lymphopenia, GvHD, high-dose steroids or other immunosuppressive drugs represent well-known risk factors. The clinical features of invasive mycoses after HSCT in children are similar to those observed in adults, and the diagnostic tools, including Aspergillus galactomannan antigen detection, are feasible also in pediatrics. Mortality due to invasive mycoses after HSCT in children is high.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545231     DOI: 10.1038/bmt.2008.67

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.

Authors:  J A Hol; T F W Wolfs; M B Bierings; C A Lindemans; A B J Versluys; A Wildt de; C E Gerhardt; J J Boelens
Journal:  Bone Marrow Transplant       Date:  2013-10-14       Impact factor: 5.483

2.  Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  K Yoshikawa; Y Nakazawa; Y Katsuyama; K Hirabayashi; S Saito; T Shigemura; M Tanaka; R Yanagisawa; K Sakashita; K Koike
Journal:  Infection       Date:  2014-02-25       Impact factor: 3.553

3.  Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Authors:  Nita L Seibel; Aziza T Shad; Ihor Bekersky; Andreas H Groll; Corina Gonzalez; Lauren V Wood; Paul Jarosinski; Donald Buell; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 4.  Clinical aspects of invasive candidiasis in paediatric patients.

Authors:  Elio Castagnola; Silvia Buratti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study.

Authors:  Yae-Jean Kim; Ki Woong Sung; Hye Sook Hwang; Shin Han Jung; Ju Youn Kim; Eun Joo Cho; Su Jin Lim; Young Bae Choi; Hee Won Cheuh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

6.  A real time PCR assay on blood for diagnosis of invasive candidiasis in immunocompromised patient.

Authors:  M Ashrafi; M Nabili; T Shokohi; G Janbabaie; M T Hedayati; K Ali-Moghaddam
Journal:  Curr Med Mycol       Date:  2015-03

Review 7.  Invasive Aspergillosis in Children: Update on Current Guidelines.

Authors:  Athanasia Apsemidou; Nikolaos Petridis; Timoleon-Achilleas Vyzantiadis; Athanasios Tragiannidis
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

Review 8.  Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children.

Authors:  Jill King; Zoi-Dorothea Pana; Thomas Lehrnbecher; William J Steinbach; Adilia Warris
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.